Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial

@article{Lima2008TransplantationOE,
  title={Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial},
  author={Marcos G. Lima and JohnD. McMannis and Adrian Philip Gee and Krishna Komanduri and D Couriel and Borje S. Andersson and Chitra M Hosing and I Khouri and R Jones and R. E. Champlin and Safa Karandish and Tahereh Sadeghi and Tony Peled and Frida Grynspan and Yaron Daniely and Arnon Nagler and Elizabeth J Shpall},
  journal={Bone Marrow Transplantation},
  year={2008},
  volume={41},
  pages={771-778}
}
The copper chelator tetraethylenepentamine (TEPA; StemEx) was shown to attenuate the differentiation of ex vivo cultured hematopoietic cells resulting in preferential expansion of early progenitors. A phase I/II trial was performed to test the feasibility and safety of transplantation of CD133+ cord blood (CB) hematopoietic progenitors cultured in media containing stem cell factor, FLT-3 ligand, interleukin-6, thrombopoietin and TEPA. Ten patients with advanced hematological malignancies were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS